This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Holmes, D. Cancer drug's survivin suppression called into question. Nat Med 18, 842–843 (2012). https://doi.org/10.1038/nm0612-842b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0612-842b
This article is cited by
-
miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer
Breast Cancer Research and Treatment (2015)
-
DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets
Nature Chemical Biology (2014)
-
Monitoring Survivin Expression in Cancer: Implications for Prognosis and Therapy
Molecular Diagnosis & Therapy (2013)